Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Rectal Neoplasms 1Neoplasm Metastasis 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Oxaliplatin 5Leucovorin 5Capecitabine 5Fluorouracil 4Erlotinib Hydrochloride 4Trastuzumab 3trametinib 2pembrolizumab 2Sorafenib 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Lapatinib 2Interleukin-12 Subunit p35 2Gemcitabine 2Floxuridine 2Chemotherapy, Adjuvant 2AZD 6244 2tremelimumab 1tivozanib 1tipifarnib 1motexafin lutetium 1ixabepilone 1entinostat 1durvalumab 1dehydroftorafur 1cediranib 1Watchful Waiting 1Specimen Handling 1Radiotherapy 1Radiofrequency Ablation 1Phototherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Bile Duct Neoplasms × Cryosurgery × Clear all
NCT02821754 2023-03-28

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
54 enrolled 14 charts
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡